Persistent tailoring of MSC activation through genetic priming

Area of Science:

• Cellular and Molecular Medicine
• Immunology
• Regenerative Medicine

Background:

• Mesenchymal stem/stromal cells (MSCs) show therapeutic promise but require priming to enhance efficacy.
• Current priming methods have limitations, including transient effects and potential immunogenicity.
• Controlled activation of MSCs is crucial for optimizing cell therapy.

Approach:

• Developed a 'genetic priming' strategy using controlled expression of the IRF1 transcription factor in MSCs.
• Engineered MSCs to hyper-express IRF1, mimicking responses to biochemical priming with interferon-γ (IFNγ).
• Evaluated the persistence and immunomodulatory effects of IRF1-mediated genetic priming.

Key Points:

• IRF1 genetic priming sustainably boosts MSC potency and anti-inflammatory molecule expression.
• This method enhances MSCs' ability to suppress T cell activation.
• IRF1 priming circumvents IFNγ-induced expression of immunogenic MHC class II molecules, unlike biochemical priming.

Conclusions:

• Genetic priming offers a persistent and controllable method for activating MSCs.
• This approach allows for selective tailoring of MSC responses for therapeutic applications.
• IRF1-mediated genetic priming represents a significant advancement in programming MSCs for enhanced cell therapy.